CRISPR Therapeutics (NASDAQ:CRSP) Earns Buy Rating from HC Wainwright
HC Wainwright reissued their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $65.00 price objective on the stock. Several other research analysts have also commented on the stock. Truist Financial lifted their price target on shares […]
HC Wainwright reissued their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. The firm currently has a $65.00 price objective on the stock. Several other research analysts have also commented on the stock. Truist Financial lifted their price target on shares […]
